二十四甘醇 | 2243942-52-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 二十四甘醇
• 英文名称: PEG-1000
• 英文别名: HO-Peg24-OH；2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol
• CAS: 2243942-52-9
• 化学式: C₄₈H₉₈O₂₅
• 分子量: 1075.29
• InChiKey: IEXKUCOGQITOPO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -4.5
• 重原子数：
  73
• 可旋转键数：
  70
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  253
• 氢给体数：
  2
• 氢受体数：
  25

反应信息

• 作为反应物：
  描述：

  二十四甘醇 在 ammonium hydroxide 、 四丁基溴化铵 、 lithium 、 三乙胺 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 57.0h， 生成 氨基-PEG24-羧酸 盐酸盐
  参考文献：
  名称：

  一种氨基聚乙二醇丙酸的制备方法

  摘要：

  本发明公开了一种氨基聚乙二醇丙酸(NH2‑PEGn‑CH2CH2C00H，n＝1‑24)的制备方法，该制备方法以单分散小分子的双羟基聚乙二醇为原料，经过磺酰化，氨化，水解得到纯品。该方法操作简单，反应条件温和，纯化容易，能获得均一稳定的产物。

  公开号：

  CN107235848B

文献信息

• Identification of Parthenolide Dimers as Activators of Pyruvate Kinase M2 in Xenografts of Glioblastoma Multiforme in Vivo
  作者：Yahui Ding、Qingqing Xue、Shuo Liu、Kai Hu、Da Wang、Tianpeng Wang、Ye Li、Hongyu Guo、Xin Hao、Weizhi Ge、Yan Zhang、Ang Li、Jing Li、Yue Chen、Quan Zhang

  DOI：10.1021/acs.jmedchem.9b01328

  日期：2020.2.27

  knockdown assay demonstrated that the anti-GBM effect of 5 mainly depended on the expression of PKM2 in vitro and in vivo. Compound 16, a prodrug of 5, markedly suppressed U118 tumor xenograft growth and reduced the weight of tumor. On the basis of these investigations, we propose that 16 might be considered as a promising lead compound for discovery of anti-GBM drugs.

  在本文中，我们详细介绍了一系列作为PKM2激活剂的酚类二聚体的发现及其抗GBM活性的评估。最有前途的化合物5表现出以15 nM的AC50值激活PKM2的高效能，抑制增殖和转移，并诱导GBM细胞凋亡。化合物5可以促进GBM细胞中PKM2的四聚体形成并减少PKM2的核易位，而不影响总PKM2的表达，从而在体外和体内抑制STAT3信号通路。PKM2敲低分析表明5的抗GBM作用主要取决于体外和体内PKM2的表达。化合物16（5的前药）显着抑制了U118肿瘤异种移植的生长并减轻了肿瘤的重量。根据这些调查，
• [EN] REACTIVE SURFACTANTS<br/>[FR] TENSIOACTIFS RÉACTIFS
  申请人：STEPAN CO

  公开号：WO2020185513A1

  公开（公告）日：2020-09-17

  Processes for making reactive surfactants are disclosed. In one such process, a fatty epoxide, a glycidyl ether, or a combination thereof is reacted with an olefin-functional nucleophile to produce an olefin-functional hydrophobe. The olefin-functional hydrophobe is reacted with ethylene oxide, propylene oxide, butylene oxides, or a combination thereof to produce an alkoxylate. Optionally, the alkoxylate is converted to the corresponding sulfate, phosphate, or maleate. Surfactant compositions comprising the reactive surfactants made by these processes are also described. The invention includes polymerizable mixtures comprising an acrylic monomer and the surfactant compositions as well as aqueous acrylic latex emulsions and coatings produced from the emulsions. The reactive surfactants deliver stable latex emulsions with reduced tendency for surfactant migration or excessive foaming. Coatings from the emulsions have improved wet adhesion, scrub resistance, and water resistance.

  揭示了制备反应性表面活性剂的方法。在其中一种方法中，脂肪环氧化物、环氧乙醚或二者的组合物与烯烃官能核糖核发生反应，从而产生烯烃官能亲水基。将烯烃官能亲水基与环氧乙烷、丙烯酸丙烯酯、丁烯氧化物或二者的组合物发生反应，制备烷氧基化物。可选地，将烷氧基化物转化为相应的硫酸盐、磷酸盐或马来酸盐。还描述了由这些方法制备的含有反应性表面活性剂的表面活性剂组合物。该发明还包括包含丙烯酸单体和表面活性剂组合物的可聚合混合物，以及由这些乳液制备的水性丙烯酸乳胶乳液和涂料。反应性表面活性剂可提供稳定的乳胶乳液，减少表面活性剂迁移或过度起泡的倾向。从这些乳液中制备的涂料具有改善的湿附着力、耐擦洗性和耐水性。
• POLYMER-CARBOHYDRATE-LIPID CONJUGATES
  申请人：Wu Nian

  公开号：US20120202979A1

  公开（公告）日：2012-08-09

  The invention comprises compounds, methods of making, and methods of using. The compounds may have a backbone and three appended functional groups: one lipid, one hydrophilic polymer, and one carbohydrate. Specific functional groups may be selected for specific applications in formulating pharmaceuticals, cosmetics, nutriceuticals, and the like. A variety of linkers between the backbone and functional groups may also be selected to optimize performance.

  该发明包括化合物、制备方法和使用方法。这些化合物可能具有一个骨架和三个附加的功能基团：一个脂质、一个亲水性聚合物和一个碳水化合物。可以选择特定的功能基团用于配制制药、化妆品、营养保健品等特定应用。还可以选择各种连接剂来优化性能。
• Compositions with improved intravitreal half-life and uses thereof
  申请人：Vitrisa Therapeutics, Inc.

  公开号：US10308943B2

  公开（公告）日：2019-06-04

  Provided herein are compositions and methods for the treatment of retinal diseases. The compositions and methods include a therapeutic agent conjugated to a vitreous component binding moiety. The vitreous component binding moiety may be an aptamer or a small molecule that binds to a structural component of the vitreous humor (e.g., hyaluronic acid, collagen or vitronectin).

  本文提供了用于治疗视网膜疾病的组合物和方法。这些组合物和方法包括与玻璃体成分结合分子共轭的治疗剂。玻璃体成分结合分子可以是与玻璃体结构成分（如透明质酸、胶原蛋白或玻璃连蛋白）结合的配合物或小分子。
• Gel of sodium hyaluronate cross-linked by polyethylene glycol epoxy derivative for injection and preparation method thereof
  申请人：JENKEM TECHNOLOGY CO., LTD. (BEIJING)

  公开号：US11191870B2

  公开（公告）日：2021-12-07

  The present invention discloses polyglycol epoxide crosslinked sodium hyaluronate gel for injection and a preparation method thereof. A polyglycol epoxide is a compound with single molecular weight preferably; a plurality of ether bonds are present in the molecule of the polyglycol epoxide, the water solubility is good, and thus, the polyglycol epoxide is more easily subjected to a crosslinking reaction with polysaccharides; and meanwhile, polyglycol is relatively easy in adjustment of the number of repeating units and relatively easy in control of length, and thus, the sodium hyaluronate gel prepared by taking the polyglycol epoxide as a crosslinker is relatively easy in regulation and control of properties. The crosslinked sodium hyaluronate gel is low in toxicity, little in residual, small in squeezing and pushing force, good in shaping performance, good in enzyme resistance and long in in-vivo retention time. The present invention further discloses a mild crosslinker deactivation technology. Unreacted epoxide groups in the gel are subjected to a hydrolysis reaction in a carbonate buffer system with a pH of 8-9, so that the difficulty of impurity removal of the crosslinked sodium hyaluronate gel can be effectively lowered, and the problem of toxicity in the prior art due to the fact that BDDE is used in a crosslinking method is avoided.

  本发明公开了注射用聚乙二醇环氧化物交联透明质酸钠凝胶及其制备方法。聚乙二醇环氧化物是优选的单分子量化合物，聚乙二醇环氧化物分子中存在多个醚键，水溶性好，因此更容易与多糖发生交联反应；同时，聚乙二醇比较容易调节重复单元的数量，也比较容易控制长度，因此以环氧聚乙二醇为交联剂制备的透明质酸钠凝胶比较容易调节和控制性质。交联后的透明质酸钠凝胶毒性低、残留少、挤压推力小、成型性能好、耐酶性好、体内存留时间长。本发明进一步公开了一种温和的交联剂失活技术。凝胶中未反应的环氧基团在 pH 值为 8-9 的碳酸盐缓冲体系中进行水解反应，从而有效降低了交联透明质酸钠凝胶的杂质去除难度，避免了现有技术中因交联方法中使用 BDDE 而产生的毒性问题。